Verve Therapeutics, Inc. (VERV) has 48 open-market insider trades by 18 insiders since 2021. The most active filer is Sekar Kathiresan, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Krishna Yeshwant | Dir10% Owner | — | 4 | $25.4M | 2025-07-25 |
| Casdin Partners Master Fund, L.P. | 10% Owner | — | 1 | $20.9M | 2021-06-21 |
| Redmile Group, LLC via Jeremy Green | 10% Owner | — | 1 | $19.9M | 2021-06-21 |
| FMR LLC | 10% Owner | — | 7 | $19.2M | 2022-07-12 |
| Sekar Kathiresan | CEO | — | 8 | $11.2M | 2025-07-25 |
| Logos Global Management LP | 10% Owner | — | 1 | $7.0M | 2021-06-21 |
| Novo Holdings A/S | 10% Owner | — | 1 | $6.7M | 2021-06-21 |
| Cormorant Global Healthcare Master Fund, LP | Dir | — | 1 | $5.2M | 2021-06-21 |
| Andrew Bellinger | CMOCSO | — | 7 | $4.2M | 2022-12-14 |
| GV 2017, L.P. via Krishna Yeshwant | — | — | 1 | $1.2M | 2022-11-03 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Joan Nickerson | Chief Administrative Officer | Sell | $12K | 2025-04-02 |
| Jason Politi | Chief Technical Ops. Off. | Sell | $13K | 2025-04-02 |
| Troy Lister | Chief Scientific Officer | Sell | $9K | 2025-04-02 |
| Andrew D. Ashe | — | Sell | $11K | 2025-04-02 |
| Allison Dorval | CFO | Sell | $14K | 2025-04-02 |
| Sekar Kathiresan | CEO | Sell | $41K |
Companies that share insiders with VERV, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2025-04-02 |
| Allison Dorval | CFO | Sell | $3K | 2024-12-02 |
| Andrew D. Ashe | — | Buy | $476K | 2024-05-14 |
| Joan Nickerson | Chief Administrative Officer | Sell | $12K | 2024-04-02 |
| Krishna Yeshwant | Director & 10% Owner | Buy | $18.0M | 2023-12-01 |
| Allison Dorval | CFO | Sell | $6K | 2023-11-29 |
| Andrew Bellinger | CSO & CMO | Sell | $20K | 2022-12-01 |
| Allison Dorval | CFO | Sell | $12K | 2022-11-29 |
| Krishna Yeshwant | Director & 10% Owner | Sell | $3.0M | 2022-11-04 |
| Alphabet Inc. | — | Sell | $1.5M | 2022-11-04 |